美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ARMP近 30 天 2 則 · 第 1 / 1 頁
- Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
- Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
- Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
- Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
- Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
- Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
- Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
- Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
- Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
- Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength
- Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
- Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
- Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
- Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
- H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod
- Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。